دورية أكاديمية
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
| العنوان: | Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial |
|---|---|
| المؤلفون: | de Boer, N.L. (Nadine Leonie), Brandt-Kerkhof, A. (Alexandra), Madsen, E.V.E. (Eva V. E.), Diepeveen, M. (Marjolein), Meerten, E. (Esther) van, van Eerden, R.A.G. (Ruben A G), Man, F.M. (Femke) de, Bouamar, R. (Rachida), Koolen, S.L.W. (Stijn), Hingh, I.H.J.T. (Ignace) de, Bakkers, C. (Checca), Rovers, K.P. (Koen P.), Creemers, G.J.M. (Geert-Jan), Deenen, M.J. (Maarten J.), Kranenburg, O. (Onno), Constantinides, A. (Alexander), Mathijssen, A.H.J. (Ron), Verhoef, C. (Kees), Burger, J.W.A. (Jacobus W A) |
| المصدر: | BMJ Open vol. 9 no. 12 |
| سنة النشر: | 2019 |
| المجموعة: | RePub - Publications from Erasmus University, Rotterdam |
| مصطلحات موضوعية: | colorectal cancer, dose-escalation study, intraperitoneal chemotherapy, palliative treatment, peritoneal metastases, systemic chemotherapy |
| الوصف: | INTRODUCTION: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard of care for patients with peritoneal metastases of colorectal origin with a low/moderate abdominal disease load. In case of a peritoneal cancer index (PCI) score >20, CRS-HIPEC is not considered to be beneficial. Patients with a PCI >20 are currently offered palliative systemic chemotherapy. Previous studies have shown that systemic chemotherapy is less effective against peritoneal metastases than it is against haematogenous spread of colorectal cancer. It is suggested that patients with peritoneal metastases may benefit from the addition of intraperitoneal chemotherapy to systemic chemotherapy. Aim of this study is to establish the maximum tolerated dose of intraperitoneal irinotecan, added to standard of care systemic therapy for colorectal cancer. Secondary endpoints are to determine the safety and feasibility of this treatment and to establish the pharmacokinetic profile of intraperitoneally administered irinotecan. METHODS AND ANALYSIS: This phase I, '3+3' dose-escalation, study is performed in two Dutch tertiary referral centres. The study population consists of adult pat |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | http://repub.eur.nl/pub/122754Test; urn:hdl:1765/122754 |
| DOI: | 10.1136/bmjopen-2019-034508 |
| الإتاحة: | https://doi.org/10.1136/bmjopen-2019-034508Test http://repub.eur.nl/pub/122754Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F7F71637 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bmjopen-2019-034508 |
|---|